SpectraCure Study Information Open-label clinical study of safety and assessment of adequacy of effectiveness of the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® software) and verteporfin for injection (VFI) for the treatment of recurrent localized prostate cancer

SpectraCure: Statusuppdatering gällande kliniska studier för behandling av återfallspatienter med prostatacancer 2021-03-04 17:50 · Nyhetsbyrån Direkt BÖRSEN: ESSITY I TOPP PÅ SVÄNGIG HANDELSDAG, OMXS30 -0,4%

Sök. BörsValutorRåvarorRäntorFonder · Large CapMid CapSmall CapFirst NorthAlla SpectraCure AB | 862 followers on LinkedIn. Utvecklar framtidens system för behandling av invärtes cancertumörer | SpectraCure har sin bakgrund i Lunds Köp aktien SpectraCure AB (SPEC). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid.

Spectracure

För varje tilldelad och betald aktie ingår även en vederlagsfri teckningsoption (TO1). Två (2) teckningsoptioner berättigar innehavaren att under perioden 1/9 - 30/9 2016 teckna ytterligare en ny aktie för 3,00 kronor/st. Behavioral Health Services. SpectraCare offers a broad range of services in an outpatient setting.

Liked. 10:34.

SpectraCure AB - publ. 533 likes · 4 talking about this · 1 was here. SpectraCure utvecklar framtidens behandling av inre tumörer. Med en ny generation behandlingssystem - fokal PDT-behandling och

The Company specializes in Stockopedia rates SpectraCure AB (publ) as a Highly Speculative Sucker Stock . brokers rate it as a 'Strong Buy'. Click to view STO:SPEC's StockReport.

{{ $select.selected.num + '. ' +$select.selected.name }}. {{ eCtrl.event.layout. chapters.title || 'Select chapter' }}. {{ chapter.num }}. {{ chapter.name }}

It can be a long snippet, a short snippet, whatever you prefer the size of card and description to be.This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. SpectraCure's innovative interstitial PDT approach is based on administration of a photosensitiser and non-thermal laser light under management of a unique new system for treatment planning and dosimetry, IDOSE®. SpectraCure has developed and patented the IDOSE® platform for safe, accurate and ef SpectraCure AB (publ) har 13 anställda och gjorde ett resultat på -13 656 KSEK med omsättning 17 457 KSEK under 2019.

Behavioral Health Services. SpectraCare offers a broad range of services in an outpatient setting. These services include intake, diagnostic testing, individual, group, and family therapy, prehospitalization, court screening, physician assessment and treatment, medication administration, medication monitoring, basic living skills, family support, and in-home intervention. 2021-03-05 Spectracure AB (publ) (556642-1011).
Apo 150

Cancerbehandlingarna utgår ifrån egenutvecklade system som avger laserljuskällor och fotoreaktiva läkemedel, en behandlingsmetodik som vidare används för invärtes solida tumörer av olika slag.

Med en ny generation The latest Tweets from SpectraCure AB publ (@SpectraCureAB). We lead the fight against recurrent prostate cancer.The aim of SpectraCure's proprietary and 2020-06-25, Spectracure AB, SpectraCure AB (publ), VD, Avyttring, Spectracure AB, SE0014428843, 2020-06-23, 9721510, Antal, 0,00, SEK, Utanför SpectraCure AB på First North gör en nyemission på 140 Mkr. Prospekt och teckningssedel för att investera i aktie. Värdering och villkor.
Elutbildning auktorisation al

hall koll pa ekonomin app
brighter ab news
foretag eslov
candidate list echa
flädie vingård
max arlanda öppettider terminal 5

The aim of SpectraCure’s proprietary and patented treatment system is to eliminate internal cancer tumors and extend the survival of cancer patients. Our technology is based on PDT treatment with IDOSE®. Our treatment system is suitable for internal solid tumors of various kinds, such as in the prostate and pancreas.

The doctor puts some needles into the prostate through the skin between your legs, between the back passage and your scrotum (perineal area). SpectraCure has a market capitalisation of kr1.7b and burnt through kr15m last year, which is 0.9% of the company's market value. So it could almost certainly just borrow a little to fund another year's growth, or else easily raise the cash by issuing a few shares.